drugset / Trial / NCT00051623
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.
Timeline
- Start
- 2003-05
- Primary completion
- —
- Completion
- 2004-06
Publications
- Background Bortul M, Calligaris L, Moro E, Bazzocchi M, Strami G. [Preoperative transhepatic biliary drainage in the jaundiced patient: our experience]. Ann Ital Chir. 1991 May-Jun;62(3):265-71; discussion 272. Italian.
- Results Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT, Beutler A, Guzzo C, Krueger GG. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006 Nov;33(11):2254-9. Epub 2006 Sep 1.
- Results Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007 Apr;66(4):498-505. doi: 10.1136/ard.2006.058339. Epub 2006 Nov 17.
- Results van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007 Aug;56(8):2698-707. doi: 10.1002/art.22805.
- Englbrecht M, Wang Y, Ronneberger M, Manger B, Vastesaeger N, Veale DJ, Schett G. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res (Hoboken). 2010 Jul;62(7):977-83. doi: 10.1002/acr.20161.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Infliximab | Monoclonal antibody | 10 mg/kg | Intravenous |